Publications by authors named "Steve Ommen"
Background: This study sought to evaluate short- and long-term outcomes of aortic valve (AV) intervention by decalcification or replacement for the treatment of mild to moderate calcific AV stenosis (AS) in patients undergoing transaortic septal myectomy for subaortic left ventricular outflow tract (LVOT) obstruction.
Methods: Between 2000 and 2023, study investigators identified 137 consecutive patients undergoing myectomy with or without membranectomy for mild to moderate calcific AS. Of these patients, 93 underwent surgical intervention on the AV and formed the primary cohort; 44 patients who did not undergo AV intervention were used as a control group.
Article Synopsis
- Surgical septal reduction is often considered risky in older adults, but this study evaluates the differences between younger and older patients undergoing septal myectomy for obstructive hypertrophic cardiomyopathy (oHCM).
- The study analyzed 2,663 patients over 21 years and found that older patients (65+) had higher rates of health issues like hypertension and diabetes, yet similar functional limitations when compared to younger counterparts.
- Despite some increased risks, septal myectomy is deemed safe for older patients, with a notable link between left ventricular wall asymmetry and poorer prognosis in this age group.
Article Synopsis
- Patients with hypertrophic cardiomyopathy (HCM) frequently experience cardiac arrhythmias and often require cardiac implantable electronic devices (CIED), which can lead to complications like tricuspid regurgitation (TR) needing surgery.
- In a study of 21 patients who had tricuspid valve (TV) surgery for device lead-induced TR after undergoing septal myectomy (SM) for HCM, the majority had severe TR and associated symptoms of right heart failure.
- Results showed that while the immediate surgical outcomes were acceptable, long-term survival for these patients was significantly lower (58% at 5 years) compared to other patients who had undergone SM (96%).
Article Synopsis
- * The study analyzed tissues from 97 patients with symptomatic obstructive HCM through RNA-sequencing and mass spectrometry, revealing significant differences in gene and protein expressions between males and females, though overall profiles were similar.
- * Findings indicate that HCM females show greater downregulation of hypertrophy pathways and have more differentially expressed proteins compared to control females than what is observed in males, highlighting biologically relevant sex-specific differences in disease mechanisms.
Introduction: We have previously reported that genetically positive patients have a more profound early decrease in provocable left ventricular outflow tract gradient compared to genetically negative patients utilizing mavacamten in the first 12 weeks of therapy.
Methods And Results: In this current analysis, we found that genetically positive patients have less favorable remodeling as measured by left ventricular wall thickness regression when evaluated long-term as compared to genetically negative patients, despite an overall better early response to mavacamten. The majority of genetically positive patients were maintained on only 2.
Background: Septal myectomy improves symptoms in the majority of patients with obstructive hypertrophic cardiomyopathy (HCM), but there are limited prospective data on functional outcomes after operation.
Objectives: The authors investigated quality of life measures and prevalence of sexual dysfunction before and after septal myectomy for obstructive HCM.
Methods: Between January 2018 and October 2019, 436 patients underwent transaortic septal myectomy at our clinic.
Article Synopsis
- This study investigates transcriptional dysregulation in myectomy tissue from patients with obstructive hypertrophic cardiomyopathy (HCM), revealing that hypertrophy pathways are downregulated despite their activation.
- Researchers hypothesized that miRNA and histone post-translational modifications play significant roles in this dysregulation, using techniques like miRNA-sequencing and ChIP-seq to analyze tissue samples.
- Results showed 19 differentially expressed miRNAs and thousands of histone modifications, indicating that these factors contribute to the downregulation of hypertrophy signaling, with knockout experiments suggesting their combined effect is crucial for maintaining normal transcriptional activity.
Objective: To compare early and late outcomes of septal myectomy in patients with obstructive hypertrophic cardiomyopathy who presented with residual or recurrent left ventricular outflow tract (LVOT) obstruction after previous septal-reduction therapy (SRT).
Methods: From January 1989 to March 2022, 145 patients underwent reintervention by septal myectomy for residual LVOT obstruction after previous SRT; 72 patients had previous alcohol septal ablation (ASA) and 73 had previous surgical septal myectomy. Baseline patient characteristics, echocardiographic parameters, and surgical outcomes were compared between these 2 groups.
Aim: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.
Methods: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.
Aim: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.
Methods: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease. Women with HCM tend to have a later onset but more severe disease course. However, the underlying pathobiological mechanisms for these differences remain unknown.
View Article and Find Full Text PDFObjective: To contemporaneously reappraise the incidence-rate, prevalence, and natural history of hypertrophic cardiomyopathy (HCM) in Olmsted County, Minnesota, from 1984 to 2015.
Patients And Methods: A validated medical-record linkage system collecting information for residents of Olmsted County was used to identify all cases of HCM between January 1, 1984, and December 31, 2015. After adjudication of records from Mayo Clinic and Olmsted Medical Center, data relating to diagnoses and outcomes were abstracted.
Background: We recently demonstrated that patients with atrial fibrillation (AF) and hypertrophic cardiomyopathy (HCM) have an increased risk of left atrial (LA) thrombus. In this study, we aimed to evaluate thrombus management, thrombus persistence, and thromboembolic events for HCM and non-HCM patients with AF and LA thrombus.
Methods: From a cohort of 2,155 AF patients undergoing transesophageal echocardiography (TEE) for any indication, this study included 122 patients with LA thrombus (64 HCM patients and 58 non-HCM controls).
Hypertrophic cardiomyopathy (HCM) is a genetically heterogenous condition with about half of cases remaining genetically elusive or non-genetic in origin. HCM patients with a positive genetic test (HCM) present earlier and with more severe disease than those with a negative genetic test (HCM). We hypothesized these differences may be due to and/or reflect proteomic and phosphoproteomic differences between the two groups.
View Article and Find Full Text PDFThe progress in the management of hypertrophic cardiomyopathy (HCM) over the last several decades has resulted in great improvements in quality of life and overall survival for HCM patients. Yet, sudden cardiac death (SCD) due to ventricular tachyarrhythmias is among the common causes of HCM-related mortality. SCD risk stratification is a central and often challenging domain in the care of the HCM patient.
View Article and Find Full Text PDFUltrasound Enhancing Agents with Transthoracic Echocardiography for Maximal Wall Thickness in Hypertrophic Cardiomyopathy.
Mayo Clin Proc Innov Qual Outcomes
August 2023
Objectives: To determine whether ultrasound enhancing agent (UEA) changes maximal wall thickness (WT) in hypertrophic cardiomyopathy (HCM), and if it improves correlation with magnetic resonance imaging (MRI).
Patients And Methods: A total of 107 patients with HCM were prospectively enrolled at a single tertiary referral center between July 10, 2014, and August 31, 2017, and underwent transthoracic echocardiography (TTE) with and without UEA and MRI. Maximal WT measurements were compared, and variability among the 3 modalities was evaluated using a simple linear regression analysis and paired tests and Bland-Altman plots.